BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02337907
Recruitment Status : Completed
First Posted : January 14, 2015
Last Update Posted : December 8, 2017
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The study is designed to compare the effects of BI 409306 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease

Condition or disease Intervention/treatment Phase
Alzheimer Disease Drug: Placebo Drug: BI 409306 Drug: Donepezil Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 329 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease
Actual Study Start Date : January 21, 2015
Actual Primary Completion Date : September 15, 2017
Actual Study Completion Date : October 10, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo comparator Drug: Placebo
for blinding purposes

Drug: Placebo
Experimental: BI 409306 dose 1 Drug: Placebo
for blinding purposes

Drug: BI 409306
Experimental: BI 409306 dose 2 Drug: Placebo
for blinding purposes

Drug: BI 409306
Experimental: BI 409306 dose 3 Drug: Placebo
for blinding purposes

Drug: BI 409306
Active Comparator: Active Comparator Donepezil Drug: Placebo
for blinding purposes

Drug: Donepezil
Experimental: BI 409306 dose 4 Drug: Placebo
for blinding purposes

Drug: BI 409306

Primary Outcome Measures :
  1. Cognition as measured by change from baseline in Neuropsychological Test Battery (NTB) in total z-score [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Change from baseline in Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) total score [ Time Frame: 12 weeks ]
  2. Change from baseline in Alzheimer's Disease Assessment Scale-cognitive subscale 11 item (ADAS-cog11) [ Time Frame: 12 weeks ]
  3. Change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) total score [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Patients with early signs of dementia of Alzheimer Type
  • Male and female patients with an age of at least 55 years
  • Previous use of AD medications (AChEIs, memantine) is allowed up 3 month prior to screening. Patients who are currently taking AChEIs are eligible as long as they have been using a stable dose for at least 3 months prior to screening and no change is foreseen for the duration of the study. This dose must be consistent with the product label in the concerned country. Patients currently taking memantine are excluded.
  • Patients must have at least 6 years of formal education and fluency in the test language as verbally confirmed by the patient and documented by the study investigator.
  • Patients must have a reliable study partner (per investigator judgement, for instance a family member, partner etc., guardian or, if applicable, a legal representative)

Exclusion criteria:

  • Cognitive impairment or dementia with any etiology other than AD
  • Substantial concomitant cerebrovascular disease (defined by a history of a stroke / intracranial haemorrhagia) temporally related to the onset of worsening of cognitive impairment per investigator judgement
  • Medical history or diagnosis of any of symptomatic and unstable/uncontrolled conditions per investigator judgement
  • Any other psychiatric disorders such as schizophrenia, or mental retardation
  • Previous participation in investigational drug studies of mild cognitive impairment/DAT within three months prior to screening. Having received active treatment in any other study targeting disease modification of AD like Aß immunization and tau therapies. Previous participation in studies with non-prescription medications, vitamins or other nutritional formulations is allowed.
  • Clinically significant uncompensated hearing loss in the judgment of the investigator. Use of hearing aids is allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02337907

  Hide Study Locations
United States, California
California Neuroscience Research
Sherman Oaks, California, United States, 91403
United States, Florida
Bioclinica Research
Orlando, Florida, United States, 32806
Premiere Research Institute
West Palm Beach, Florida, United States, 33407
United States, Indiana
Indiana University
Indianapolis, Indiana, United States, 46202
United States, New Jersey
Memory Enhancement Center of America, Inc.
Eatontown, New Jersey, United States, 07724
United States, New York
Psychiatry And Alzheimer's Care of Rochester, PLLC
Rochester, New York, United States, 14623
Richmond Behavioral Associates
Staten Island, New York, United States, 10312
United States, North Carolina
ANI Neurology, PLLC, dba Alzheimer's Memory Center
Charlotte, North Carolina, United States, 28270
United States, Oklahoma
Tulsa Clinical Research, LLC
Tulsa, Oklahoma, United States, 74104
United States, Vermont
The Memory Clinic
Bennington, Vermont, United States, 05201
Private Practice for Psychiatry and Neurology
Wien, Austria, 1130
Brussels-UNIV Brugmann -Horta
Brussel, Belgium, 1020
Dendermonde - HOSP St-Blasius
Dendermonde, Belgium, 9200
Gent, Belgium, 9000
Mons - UNIV Ambroise Paré
Mons, Belgium, 7000
Canada, Alberta
University of Calgary
Calgary, Alberta, Canada, T2N 4Z6
Canada, British Columbia
Dr. Alexander McIntyre Inc.
Penticton, British Columbia, Canada, V2A 4M4
Canada, Saskatchewan
Pasqua Hospital
Regina, Saskatchewan, Canada, S4T 1A5
Institut universitaire de geriatrie Sherbrooke
Quebec, Canada, J1J 3H5
HOP Pellegrin
Bordeaux Cedex, France, 33076
HOP Bocage
Dijon, France, 21079
HOP Timone
Marseille, France, 13385
HOP Chauliac
Montpellier cedex 5, France, 34295
HOP Nord Laënnec
Nantes, France, 44093
HOP La Pitié Salpêtrière
Paris, France, 75651
HOP Jean Bernard, Géria, Poitiers
Poitiers Cedex, France, 86021
Praxis Dr. med. Volker Schumann
Berlin, Germany, 10245
emovis GMBH, Berlin
Berlin, Germany, 10629
St. Josef- und St. Elisabeth-Hospital gGmbH
Bochum, Germany, 44791
Neuro Centrum Science GmbH
Erbach, Germany, 64711
AFL Arzneimittelforschung Leipzig GmbH
Leipzig, Germany, 04107
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Germany, 55131
Zentralinstitut für seelische Gesundheit
Mannheim, Germany, 68159
Universitätsklinikum Ulm
Ulm, Germany, 89081
Neurologie und Psychiatrie / Psychotherapie
Westerstede, Germany, 26655
P.O. Bellaria IRCCS Istituto delle scienze Neurologiche di Bologna
Bologna, Italy, 40139
Azienda Ospedaliera Careggi
Firenze, Italy, 50134
Azienda Ospedaliera di Parma
Parma, Italy, 43126
Jeroen Bosch Ziekenhuis-Hertogenbosch
's-HERTOGENBOSCH, Netherlands, 5223 GZ
Brain Research Center
Amsterdam, Netherlands, 1081 GN
Podlassian Center of Psychogeriatry, Bialystok
Bialystok, Poland, 15-756
Mental Health Center Biomed
Kielce, Poland, 25-411
Non-Public Outpatient Clinic Neuromed M. i M. Nastaj
Lublin, Poland, 20-064
Inst. of Rural Health, Spec. Outp. Clin. & Rural Occup. Dis.
Lublin, Poland, 20-090
Non-Public Outpatient Clinic Neuro-Kard Ilkowski & Partners
Poznan, Poland, 61-853
Medical Center Senior
Sopot, Poland, 81-855
EUROMEDIS Sp. z o.o., Szczecin
Szczecin, Poland, 70-111
Reg. Specialist Hospital Wroclaw, Research & Develop. Center
Wroclaw, Poland, 51-124
Hospital Fernando Fonseca, EPE
Amadora, Portugal, 2700-276
Hospital de Braga-Escala Braga
Braga, Portugal, 4710-243
CHUC - Centro Hospitalar e Universitário de Coimbra, EPE
Coimbra, Portugal, 3000-075
Hospital Senhora Oliveira Guimarães,EPE
Guimarães, Portugal, 4835-044
CHLO, EPE - Hospital Egas Moniz
Lisboa, Portugal, 1349-019
Hospital Beatriz Ângelo
Loures, Portugal, 2674-514
ULSM, EPE - Hospital Pedro Hispano
Matosinhos, Portugal, 4454-509
Centro Hospitalar de Entre o Douro e Vouga, E.P.E. - Hospital de São Sebastião
Santa Maria da Feira, Portugal, 4520-211
United Kingdom
Royal United Hospital
Bath, United Kingdom, BA1 3NG
Ninewells Hospital & Medical School
Dundee, Scotland, United Kingdom, DD19SY
West Devon (Tavistock) CMHT & Memory Clinic (EDI)
Ivybridge, United Kingdom, PL219AB
Re-Cognition Health
Plymouth, United Kingdom, PL6 8BT
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Responsible Party: Boehringer Ingelheim Identifier: NCT02337907     History of Changes
Other Study ID Numbers: 1289.7
2013-005040-28 ( EudraCT Number )
First Posted: January 14, 2015    Key Record Dates
Last Update Posted: December 8, 2017
Last Verified: December 2017

Additional relevant MeSH terms:
Alzheimer Disease
Cognitive Dysfunction
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cognition Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents